ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apalutamide

Also written as “Apalutamide”, “JNJ-56021927” and “ARN-509”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Salivary Gland Neoplasms, led by 2 companies.

Drug pageApalutamide: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 26, 201928 company-led studies, 11 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only2711 open or runningphase 4since Sep 26, 2019Jul 27, 2010Dec 1, 2026phase 3 · NCT03767244
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead

Also a collaborator on its studies: Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sumitomo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named apalutamideINNProposed as its International Nonproprietary Name in WHO's List 113 · before, JNJ-56021927, ARN-509, JNJ 56021927
  2. Dec 7, 2020First study: phase 1 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT04666129 · 48 enrolled · United States

TargetBeta

AR →read by rule
“A small molecule and androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

The one study Sumitomo Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedMay 28, 202448

How it is read

Names in the registry

  • “Apalutamide”, 18 entries
  • “JNJ-56021927”, 4 entries
  • “ARN-509”, 3 entries
  • “JNJ 56021927”, 1 entry
  • “apalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.